4.55
0.66%
+0.03
After Hours:
4.55
Edesa Biotech Inc stock is currently priced at $4.55, with a 24-hour trading volume of 14,220.
It has seen a +0.66% increased in the last 24 hours and a +3.41% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.51 pivot point. If it approaches the $4.55 resistance level, significant changes may occur.
Previous Close:
$4.52
Open:
$4.39
24h Volume:
14,220
Market Cap:
$14.63M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-1.8056
EPS:
-2.52
Net Cash Flow:
$-6.25M
1W Performance:
-1.30%
1M Performance:
+3.41%
6M Performance:
+51.16%
1Y Performance:
+384.04%
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
289 800 9600
Address
100 Spy Court, Markham, ON
Edesa Biotech Inc Stock (EDSA) Latest News
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024 - MSN
MSN
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results - 10.05.2024 - wallstreet:online
wallstreet:online
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results | Regional | chronicle-tribune.com - Chronicle-Tribune
Chronicle-Tribune
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results - 10.05.2024 - wallstreet:online
wallstreet:online
EDSA Stock Quote Price and Forecast - CNN
CNN
Edesa Biotech Reports Fiscal Year 2023 Results - Yahoo Finance
Yahoo Finance
Edesa Biotech Inc Stock (EDSA) Financials Data
Edesa Biotech Inc (EDSA) Net Income 2024
EDSA net income (TTM) was -$7.72 million for the quarter ending December 31, 2023, a +50.22% increase year-over-year.
Edesa Biotech Inc (EDSA) Cash Flow 2024
EDSA recorded a free cash flow (TTM) of -$6.25 million for the quarter ending December 31, 2023, a +42.45% increase year-over-year.
Edesa Biotech Inc (EDSA) Earnings per Share 2024
EDSA earnings per share (TTM) was -$2.6394 for the quarter ending December 31, 2023, a +61.64% growth year-over-year.
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Cap:
|
Volume (24h):